1. , , , Characterization of a pluripotent stem cell line derived from a mouse embryo. Exp Cell Res 1984; 152:212–19.
2. , , Characterization and differentiation of human embryonic stem cells. Cloning Stem Cells 2003; 5:79–88.
3. Stem cells today: A. Origin and potential of embryo stem cells. Reprod Biomed Online 2004; 8:275–306.
4. In vitro fertilization: past and future. Ann Biol Clin 1987; 45:321–9.
5. , , , et al. Embryonic stem cells as an alternate marrow donor source: engraftment without graft-versus-host disease. J Exp Med 2004; 199:895–904.
6. , , , et al. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol 2001; 19:1129–33.
7. , , , et al. Neuralprogenitors from human embryonic stem cells. Nat Biotechnol 2001; 19:1134–40.
8. , , , A subset of ES-cell-derived neural cells marked by gene targeting. Stem Cells 2003; 21:41–9.
9. , , , et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transpl 2001; 28:1–12.
10. , , , et al. Multiple sclerosis flares associated with recombinant granulocyte colonystimulating factor. Neurology 2000; 54:2147–50.
11. , , , et al. Effect of hematopoietic growth factors on severity of experimental autoimmune encephalomyelitis. Bone Marrow Transpl 2006; 38(6):453–60.
12. , , , et al. Bone marrow as a potential source of hepatic oval cells. Science 1999; 284:1168–70.
13. , , , et al. Multiorgan, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 2001; 105:369–77.
14. , , , et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410:701–5.
15. , Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci USA 1997; 94:4080–5.
16. , , Bone marrow transplantation for multiple sclerosis. Bone Marrow Transpl 1995; 16:1–6.
17. T cell anergy. Annu Rev Immunol 2003; 21:305–34.
18. , , , et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005; 201:805–16.
19. , , , T-cell clones persisting in the circulation after autologous hematopoietic SCT are undetectable in the peripheral CD34+ selected graft. Bone Marrow Transpl 2010 Feb; 45(2):325–31.
20. , , , et al. Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis. Blood 1998; 91:2609–16.
21. , , , et al. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J Immunol 1992; 148:1693–8.
22. , Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation. Bone Marrow Transpl 1996; 18:1029–34.
23. , Treatment of relapsing experimental autoimmune encephalomyelitis with largely MHC-mismatched allogeneic bone marrow transplantation. Transplantation 1996; 62:810–18.
24. , , , et al. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high-dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J Clin Invest 1993; 92:765–72.
25. , , Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT. Bone Marrow Transpl 1993; 11:233–41.
26. , , , et al. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat Med 1997; 3:1133–6.
27. , , , Viral hyperinfection of the central nervous system and high mortality after hematopoietic stem cell transplantation for treatment of Theiler's murine encephalomyelitis virus-induced demyelinating disease. Blood 1999; 94:2915–22.
28. , , , et al. Risks of immune system treatments. Science 2010; 328(5980):825–6.
29. , , , Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. J Am Med Assoc 2008 Feb 27; 299(8):925–36.
30. , , , et al. Irradiation induces neural precursor-cell dysfunction. Nat Med 2002; 8:955–62.
31. , , , et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood 2007 Mar 15; 109(6):2643–8.
32. , , , et al. Autologous stem cell transplantation in progressive multiple sclerosis – an interim analysis of efficacy. J Clin Immunol 2000; 20:24–30.
33. , , , et al. Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis. Transplant Proc 2001; 33:2179–81.
34. , , , et al. Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology 2004; 62:282–4.
35. , , , et al. Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurologia 2008 Sep; 23(7):405–7.
36. , , , et al. Autologous hematopoietic stem cell transplantation suppresses Gd enhanced MRI activity in MS. Neurology 2001; 57:62–8.
37. , , , et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003; 102:2373–8.
38. , , , et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003; 102:2364–72.
39. , , , et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transpl 2000; 6:563–75.
40. , , , et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multi-center study. J Neurol 2002; 249:1088–97.
41. , , , et al. Autoimmune Diseases Working Party of EBMT. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 2006; 12(6):814–23.
42. , , , et al. Autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Int J Hematol 2006; 84(3):276–81.
43. , , , et al. Clinical outcomes after autologous haematopoietic stem cell transplantation in patients with progressive multiple sclerosis. Chin Med J (Engl) 2006; 119(22):1851–5.
44. , , , , Autologous hematopoietic stem celltransplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin Transpl 2006; 20(4):485–9.
45. , , , et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry 2006; 77:46–50.
46. , , , et al High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol 2008; 36(8):922–8.
47. , , Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult Scler 2009; 15(2):229–37.
48. , , , et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009; 8(3):244–53. Epub 2009 Jan 29. Erratum in: Lancet Neurol. 2009; 8(4):309.
49. , , , et al. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. Bone Marrow Transpl 2010; 45(2):239–48.
50. , , , et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transpl 1997; 20(8):631–8.
ASTI MS (Autologous Stem cell Transplantation International Multiple Sclerosis). Available from: http://www
53. , Suppressing immunity in advancing MS: too much too late, or too late for much? Neurology 2004; 62(2):168–9.
54. , , , et al. Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. Mult Scler 2005; 11(3):367–71.
55. , , , et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 2005; 105:2601–7.
58. , , et al. Neuroinflammation and demyelination in multiple sclerosis after allogeneic hematopoietic stem cell transplantation. Arch Neurol 2010; 67(6):716–22.
59. , , , et al. Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation. Arch Neurol. 2009; 66(1):116–20.
60. , , , et al. Hematopoietic mixed chimerism derived from allogeneic embryonic stem cells prevents autoimmune diabetes mellitus in NOD mice. Stem Cells 2008; 26(2):381–6.
61. , , , et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99:3838–43.
62. , , , et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106:1755–61.
63. , Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105:1815–22.
64. , , Mechanisms of and perspectives on the mesenchymal stem cells in immunotherapy. J Lab Clin Med 2003; 143:284–91.
65. , , , et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009; 57:1192–203.
66. , , , Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther 2009; 17:1799–803.
67. , , , et al. Mesenchymal stem cells for treatment of steroidresistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371:1579–86.
68. , , , et al. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult Scler 2009; 15:644–6.
69. , , et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol 2007; 4:50–7.
70. , , , et al. Systematic chromosomal aberrations found in murine bone marrow-derived mesenchymal stem cells. Stem Cells Dev 2010; 19(8):1167–73.
71. , , , et al; Canadian MS BMT Study Group. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 2006; 66(12):1935–7.
72. , , et al. Italian GITMO-NEURO Intergroup on Autologous Stem Cell Transplantation. The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Mult Scler 2007; 13(8):1068–70.